Jiawei Yanghe Decoction suppresses breast cancer by regulating immune responses via JAK2/STAT3 signaling pathway

You, Yanting; Chen, Xiaomei; Chen, Xiaohu; Li, Hong; Zhou, Ruisi; Zhou, Jie; Chen, Meilin; Peng, Baizhao; Ji, Shuai; Kwan, Hiu Yee; Zou, Lifang; Yu, Jie-Ping; Liu, Yanyan; Wu, Yang; Zhao, Xiaoshan

doi:10.1016/j.jep.2023.116358

Cited by 10 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, research into the regulation of inflammation by TCM and its compounds is being conducted progressively. For instance, the Jiawei-Yanghe decoction has been shown to reduce the expression levels of IL-1β, IL-6, TNFα, PTGS2, and VEGFα in BC tissues, and thereby decrease the expressions of M2 macrophages and Treg cells with increased expressions of M1 macrophages [31] . Norcantharidin, an effective IL-6 inhibitor, enhances the antitumor activity of sorafenib in a rat model of hepatocellular carcinoma through the IL-6–STAT3 pathway [32] .…”

Section: Discussionmentioning

confidence: 99%

<italic>Xianling Lianxia</italic> formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer

Li,

Wu,

Shi

et al. 2024

ABBS

View full text Add to dashboard Cite

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is characterized by high invasiveness. Trastuzumab considerably improves the prognoses of HER2-positive BC, but some patients exhibit drug resistance. In this study, the effects of XLLXF combined with trastuzumab on the proliferation, apoptosis, invasion, and migration of HER2-positive BC cells are evaluated, and network pharmacology is performed. Then, we conduct an in vivo study using a xenograft mouse model of HER2-positive BC, and tumor growth is monitored. The expression levels of cytokines are measured by ELISA. Molecular docking is performed to observe the binding stability of IL2, JAK, STAT, and TNF with curcumenol, icariside-II, lobetyolin, and scutellarein. Finally, we observe changes in JAK1 and TNF-α in tumor tissues by immunohistochemistry. The results show that XLLXF enhances the inhibitory effects of trastuzumab on the proliferation, colony formation ability, migration, and invasion of HER2-positive BC cells and promotes apoptosis. Network pharmacology reveals that XLLXF may exert its effects on HER2-positive BC by modulating pathways such as the ErbB, JAK-STAT, and NF-κB pathways. Potential targets include cytokines closely related to immune function. In the in vivo study, XLLXF synergistically enhances the inhibitory effects of trastuzumab on tumor growth. ELISA reveals that XLLXF combined with trastuzumab increases the levels of IL-15, IL-2, TNF-α, and IFN-γ in tumor-bearing mice. Immunohistochemistry confirms that XLLXF can regulate the expressions of JAK1 and TNF-α. This study demonstrates that XLLXF can synergistically enhance the efficacy of trastuzumab in targeting HER2-positive BC. The mechanism may involve the modulation of inflammatory factors.

show abstract

Section: Discussionmentioning

confidence: 99%

<italic>Xianling Lianxia</italic> formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer

Li,

Wu,

Shi

et al. 2024

ABBS

View full text Add to dashboard Cite

show abstract

“…42 Yanghe Tang can enhance the efficacy of chemotherapy and can inhibit inflammation and improve the body's microenvironment and immunity. 43,44 The Chemical Compounds Isolated from Chinese Herbs for BC…”

Section: Treatment Complicationsmentioning

confidence: 99%

Traditional Chinese Medicine for Breast Cancer: A Review

Feng,

Li,

Liu

et al. 2023

BCTT

View full text Add to dashboard Cite

A total of 18% of global breast cancer (BC) deaths are attributed to BC in China, making it one of the five most common cancers there. There has been a steady rise in BC morbidity and mortality in women in the last few years and it is now a leading cancer among Chinese women. Conventional treatments for BC are currently effective but have several limitations and disadvantages, and Traditional Chinese medicine (TCM) plays a vital role in the overall process of cancer prevention and therapy. It is known that TCM can treat a variety of conditions at a variety of sites and targets. In recent years, increasingly, research has been conducted on TCM’s ability to treat BC. TCM has shown positive results in the treatment of breast cancer and the adverse effects of radiotherapy and chemotherapy. This review describes the progress of clinical observation and mechanism research of TCM in the treatment of breast cancer in recent years. It provides some ideas and theoretical basis for the treatment of BC with TCM.

show abstract

Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis

Xu,

Liu,

Liu

et al. 2023

Biochemical Pharmacology

View full text Add to dashboard Cite

Jiawei Yanghe Decoction suppresses breast cancer by regulating immune responses via JAK2/STAT3 signaling pathway

Cited by 10 publications

References 43 publications

<italic>Xianling Lianxia</italic> formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer

<italic>Xianling Lianxia</italic> formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer

Traditional Chinese Medicine for Breast Cancer: A Review

Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis

Contact Info

Product

Resources

About

Jiawei Yanghe Decoction suppresses breast cancer by regulating immune responses via JAK2/STAT3 signaling pathway

Cited by 10 publications

References 43 publications

&lt;italic&gt;Xianling Lianxia&lt;/italic&gt; formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer

&lt;italic&gt;Xianling Lianxia&lt;/italic&gt; formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer

Traditional Chinese Medicine for Breast Cancer: A Review

Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis

Contact Info

Product

Resources

About

<italic>Xianling Lianxia</italic> formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer

<italic>Xianling Lianxia</italic> formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer